nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—GNRHR—GPCRs, Other—GRM8—lung cancer	0.0056	0.0591	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—OXTR—lung cancer	0.00544	0.0574	CbGpPWpGaD
Gonadorelin—Pain—Pemetrexed—lung cancer	0.00525	0.0058	CcSEcCtD
Gonadorelin—Constipation—Gefitinib—lung cancer	0.00521	0.00576	CcSEcCtD
Gonadorelin—Pain—Gefitinib—lung cancer	0.00521	0.00576	CcSEcCtD
Gonadorelin—Pelvic pain—Doxorubicin—lung cancer	0.00517	0.00571	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Pemetrexed—lung cancer	0.00502	0.00554	CcSEcCtD
Gonadorelin—Injection site reaction—Docetaxel—lung cancer	0.00501	0.00553	CcSEcCtD
Gonadorelin—Swelling—Etoposide—lung cancer	0.00499	0.00551	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Gefitinib—lung cancer	0.00499	0.00551	CcSEcCtD
Gonadorelin—Embolism—Doxorubicin—lung cancer	0.0049	0.00541	CcSEcCtD
Gonadorelin—Swelling—Paclitaxel—lung cancer	0.00489	0.0054	CcSEcCtD
Gonadorelin—Abdominal pain—Pemetrexed—lung cancer	0.00485	0.00536	CcSEcCtD
Gonadorelin—Abdominal pain—Gefitinib—lung cancer	0.00482	0.00533	CcSEcCtD
Gonadorelin—Asthenia—Crizotinib—lung cancer	0.00482	0.00532	CcSEcCtD
Gonadorelin—Angiopathy—Topotecan—lung cancer	0.00471	0.0052	CcSEcCtD
Gonadorelin—Immune system disorder—Topotecan—lung cancer	0.00468	0.00517	CcSEcCtD
Gonadorelin—Redness—Doxorubicin—lung cancer	0.00466	0.00514	CcSEcCtD
Gonadorelin—Diarrhoea—Crizotinib—lung cancer	0.00459	0.00508	CcSEcCtD
Gonadorelin—Hypersensitivity—Pemetrexed—lung cancer	0.00452	0.00499	CcSEcCtD
Gonadorelin—Hypersensitivity—Gefitinib—lung cancer	0.00449	0.00496	CcSEcCtD
Gonadorelin—Erythema—Erlotinib—lung cancer	0.00447	0.00493	CcSEcCtD
Gonadorelin—Asthenia—Pemetrexed—lung cancer	0.0044	0.00486	CcSEcCtD
Gonadorelin—Flatulence—Erlotinib—lung cancer	0.0044	0.00486	CcSEcCtD
Gonadorelin—Asthenia—Gefitinib—lung cancer	0.00438	0.00483	CcSEcCtD
Gonadorelin—Pruritus—Pemetrexed—lung cancer	0.00434	0.0048	CcSEcCtD
Gonadorelin—Breast disorder—Cisplatin—lung cancer	0.00434	0.00479	CcSEcCtD
Gonadorelin—Pruritus—Gefitinib—lung cancer	0.00431	0.00477	CcSEcCtD
Gonadorelin—Vomiting—Crizotinib—lung cancer	0.00427	0.00472	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Irinotecan—lung cancer	0.00425	0.00469	CcSEcCtD
Gonadorelin—Diarrhoea—Pemetrexed—lung cancer	0.0042	0.00464	CcSEcCtD
Gonadorelin—Diarrhoea—Gefitinib—lung cancer	0.00417	0.00461	CcSEcCtD
Gonadorelin—Swelling—Docetaxel—lung cancer	0.00414	0.00458	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Teniposide—lung cancer	0.00406	0.00449	CcSEcCtD
Gonadorelin—Angiopathy—Vinorelbine—lung cancer	0.00403	0.00445	CcSEcCtD
Gonadorelin—Immune system disorder—Vinorelbine—lung cancer	0.00401	0.00443	CcSEcCtD
Gonadorelin—Nausea—Crizotinib—lung cancer	0.00399	0.00441	CcSEcCtD
Gonadorelin—Abdominal discomfort—Cisplatin—lung cancer	0.00398	0.0044	CcSEcCtD
Gonadorelin—Abdominal pain—Teniposide—lung cancer	0.00393	0.00434	CcSEcCtD
Gonadorelin—Vomiting—Pemetrexed—lung cancer	0.0039	0.00431	CcSEcCtD
Gonadorelin—Breast disorder—Paclitaxel—lung cancer	0.0039	0.00431	CcSEcCtD
Gonadorelin—Vomiting—Gefitinib—lung cancer	0.00388	0.00428	CcSEcCtD
Gonadorelin—Erythema—Vinorelbine—lung cancer	0.00386	0.00427	CcSEcCtD
Gonadorelin—Anaphylactic shock—Topotecan—lung cancer	0.00368	0.00407	CcSEcCtD
Gonadorelin—Hypersensitivity—Teniposide—lung cancer	0.00366	0.00405	CcSEcCtD
Gonadorelin—Nausea—Pemetrexed—lung cancer	0.00365	0.00403	CcSEcCtD
Gonadorelin—Nausea—Gefitinib—lung cancer	0.00362	0.004	CcSEcCtD
Gonadorelin—Nervous system disorder—Topotecan—lung cancer	0.00361	0.00399	CcSEcCtD
Gonadorelin—Breast pain—Doxorubicin—lung cancer	0.0036	0.00398	CcSEcCtD
Gonadorelin—Shock—Erlotinib—lung cancer	0.00359	0.00396	CcSEcCtD
Gonadorelin—Nervous system disorder—Erlotinib—lung cancer	0.00357	0.00395	CcSEcCtD
Gonadorelin—Asthenia—Teniposide—lung cancer	0.00357	0.00394	CcSEcCtD
Gonadorelin—Pruritus—Teniposide—lung cancer	0.00352	0.00389	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Paclitaxel—lung cancer	0.00346	0.00383	CcSEcCtD
Gonadorelin—Diarrhoea—Teniposide—lung cancer	0.0034	0.00376	CcSEcCtD
Gonadorelin—Angiopathy—Irinotecan—lung cancer	0.00332	0.00367	CcSEcCtD
Gonadorelin—Immune system disorder—Irinotecan—lung cancer	0.0033	0.00365	CcSEcCtD
Gonadorelin—Breast disorder—Docetaxel—lung cancer	0.0033	0.00365	CcSEcCtD
Gonadorelin—Pain—Vinblastine—lung cancer	0.00324	0.00358	CcSEcCtD
Gonadorelin—Constipation—Vinblastine—lung cancer	0.00324	0.00358	CcSEcCtD
Gonadorelin—Angiopathy—Gemcitabine—lung cancer	0.00323	0.00357	CcSEcCtD
Gonadorelin—Immune system disorder—Gemcitabine—lung cancer	0.00322	0.00356	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Topotecan—lung cancer	0.00318	0.00351	CcSEcCtD
Gonadorelin—Fatigue—Topotecan—lung cancer	0.00318	0.00351	CcSEcCtD
Gonadorelin—Vomiting—Teniposide—lung cancer	0.00316	0.00349	CcSEcCtD
Gonadorelin—Anaphylactic shock—Vinorelbine—lung cancer	0.00315	0.00348	CcSEcCtD
Gonadorelin—Constipation—Topotecan—lung cancer	0.00315	0.00348	CcSEcCtD
Gonadorelin—Pain—Topotecan—lung cancer	0.00315	0.00348	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Erlotinib—lung cancer	0.00315	0.00348	CcSEcCtD
Gonadorelin—Fatigue—Erlotinib—lung cancer	0.00314	0.00347	CcSEcCtD
Gonadorelin—Flatulence—Irinotecan—lung cancer	0.00314	0.00347	CcSEcCtD
Gonadorelin—Injection site reaction—Doxorubicin—lung cancer	0.00312	0.00345	CcSEcCtD
Gonadorelin—Constipation—Erlotinib—lung cancer	0.00312	0.00344	CcSEcCtD
Gonadorelin—Pain—Erlotinib—lung cancer	0.00312	0.00344	CcSEcCtD
Gonadorelin—Headache—Teniposide—lung cancer	0.00311	0.00344	CcSEcCtD
Gonadorelin—Erythema—Gemcitabine—lung cancer	0.0031	0.00343	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Vinblastine—lung cancer	0.0031	0.00343	CcSEcCtD
Gonadorelin—Nervous system disorder—Vinorelbine—lung cancer	0.00309	0.00341	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Topotecan—lung cancer	0.00301	0.00333	CcSEcCtD
Gonadorelin—Immune system disorder—Cisplatin—lung cancer	0.003	0.00331	CcSEcCtD
Gonadorelin—Abdominal pain—Vinblastine—lung cancer	0.003	0.00331	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Erlotinib—lung cancer	0.00298	0.00329	CcSEcCtD
Gonadorelin—Nausea—Teniposide—lung cancer	0.00295	0.00326	CcSEcCtD
Gonadorelin—Abdominal pain—Topotecan—lung cancer	0.00291	0.00322	CcSEcCtD
Gonadorelin—Erythema—Cisplatin—lung cancer	0.00289	0.00319	CcSEcCtD
Gonadorelin—Abdominal pain—Erlotinib—lung cancer	0.00288	0.00318	CcSEcCtD
Gonadorelin—Flatulence—Cisplatin—lung cancer	0.00285	0.00315	CcSEcCtD
Gonadorelin—Hypersensitivity—Vinblastine—lung cancer	0.00279	0.00309	CcSEcCtD
Gonadorelin—Angiopathy—Etoposide—lung cancer	0.00276	0.00305	CcSEcCtD
Gonadorelin—Immune system disorder—Etoposide—lung cancer	0.00275	0.00304	CcSEcCtD
Gonadorelin—Asthenia—Vinblastine—lung cancer	0.00272	0.00301	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00272	0.00301	CcSEcCtD
Gonadorelin—Fatigue—Vinorelbine—lung cancer	0.00272	0.003	CcSEcCtD
Gonadorelin—Hypersensitivity—Topotecan—lung cancer	0.00271	0.003	CcSEcCtD
Gonadorelin—Angiopathy—Paclitaxel—lung cancer	0.00271	0.00299	CcSEcCtD
Gonadorelin—Pain—Vinorelbine—lung cancer	0.0027	0.00298	CcSEcCtD
Gonadorelin—Constipation—Vinorelbine—lung cancer	0.0027	0.00298	CcSEcCtD
Gonadorelin—Immune system disorder—Paclitaxel—lung cancer	0.0027	0.00298	CcSEcCtD
Gonadorelin—Asthenia—Topotecan—lung cancer	0.00264	0.00292	CcSEcCtD
Gonadorelin—Asthenia—Erlotinib—lung cancer	0.00262	0.00289	CcSEcCtD
Gonadorelin—Pruritus—Topotecan—lung cancer	0.00261	0.00288	CcSEcCtD
Gonadorelin—Anaphylactic shock—Irinotecan—lung cancer	0.0026	0.00287	CcSEcCtD
Gonadorelin—Erythema—Paclitaxel—lung cancer	0.0026	0.00287	CcSEcCtD
Gonadorelin—Diarrhoea—Vinblastine—lung cancer	0.0026	0.00287	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—GRP—lung cancer	0.00259	0.0274	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—OXTR—lung cancer	0.00259	0.0274	CbGpPWpGaD
Gonadorelin—Pruritus—Erlotinib—lung cancer	0.00258	0.00285	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Vinorelbine—lung cancer	0.00258	0.00285	CcSEcCtD
Gonadorelin—Flatulence—Paclitaxel—lung cancer	0.00256	0.00283	CcSEcCtD
Gonadorelin—Shock—Irinotecan—lung cancer	0.00256	0.00283	CcSEcCtD
Gonadorelin—Nervous system disorder—Irinotecan—lung cancer	0.00255	0.00282	CcSEcCtD
Gonadorelin—Anaphylactic shock—Gemcitabine—lung cancer	0.00253	0.0028	CcSEcCtD
Gonadorelin—Diarrhoea—Topotecan—lung cancer	0.00252	0.00278	CcSEcCtD
Gonadorelin—Diarrhoea—Erlotinib—lung cancer	0.00249	0.00276	CcSEcCtD
Gonadorelin—Abdominal pain—Vinorelbine—lung cancer	0.00249	0.00275	CcSEcCtD
Gonadorelin—Nervous system disorder—Gemcitabine—lung cancer	0.00248	0.00274	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—GNG11—lung cancer	0.00243	0.0256	CbGpPWpGaD
Gonadorelin—Vomiting—Vinblastine—lung cancer	0.00241	0.00266	CcSEcCtD
Gonadorelin—Breast disorder—Methotrexate—lung cancer	0.00238	0.00263	CcSEcCtD
Gonadorelin—Headache—Vinblastine—lung cancer	0.00238	0.00262	CcSEcCtD
Gonadorelin—Anaphylactic shock—Cisplatin—lung cancer	0.00236	0.00261	CcSEcCtD
Gonadorelin—Vomiting—Topotecan—lung cancer	0.00234	0.00259	CcSEcCtD
Gonadorelin—Hypersensitivity—Vinorelbine—lung cancer	0.00232	0.00257	CcSEcCtD
Gonadorelin—Vomiting—Erlotinib—lung cancer	0.00232	0.00256	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—lung cancer	0.00232	0.0245	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—OXTR—lung cancer	0.00232	0.0245	CbGpPWpGaD
Gonadorelin—Nervous system disorder—Cisplatin—lung cancer	0.00231	0.00256	CcSEcCtD
Gonadorelin—Headache—Topotecan—lung cancer	0.00231	0.00255	CcSEcCtD
Gonadorelin—Angiopathy—Docetaxel—lung cancer	0.00229	0.00253	CcSEcCtD
Gonadorelin—Immune system disorder—Docetaxel—lung cancer	0.00228	0.00252	CcSEcCtD
Gonadorelin—Headache—Erlotinib—lung cancer	0.00228	0.00252	CcSEcCtD
Gonadorelin—Asthenia—Vinorelbine—lung cancer	0.00226	0.0025	CcSEcCtD
Gonadorelin—Nausea—Vinblastine—lung cancer	0.00225	0.00249	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Irinotecan—lung cancer	0.00224	0.00248	CcSEcCtD
Gonadorelin—Fatigue—Irinotecan—lung cancer	0.00224	0.00248	CcSEcCtD
Gonadorelin—Pruritus—Vinorelbine—lung cancer	0.00223	0.00246	CcSEcCtD
Gonadorelin—Constipation—Irinotecan—lung cancer	0.00222	0.00246	CcSEcCtD
Gonadorelin—Pain—Irinotecan—lung cancer	0.00222	0.00246	CcSEcCtD
Gonadorelin—Erythema—Docetaxel—lung cancer	0.0022	0.00243	CcSEcCtD
Gonadorelin—Nausea—Topotecan—lung cancer	0.00219	0.00242	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00219	0.00241	CcSEcCtD
Gonadorelin—Abdominal discomfort—Methotrexate—lung cancer	0.00218	0.00241	CcSEcCtD
Gonadorelin—Fatigue—Gemcitabine—lung cancer	0.00218	0.00241	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG11—lung cancer	0.00217	0.0229	CbGpPWpGaD
Gonadorelin—Constipation—Gemcitabine—lung cancer	0.00217	0.00239	CcSEcCtD
Gonadorelin—Pain—Gemcitabine—lung cancer	0.00217	0.00239	CcSEcCtD
Gonadorelin—Nausea—Erlotinib—lung cancer	0.00217	0.00239	CcSEcCtD
Gonadorelin—Anaphylactic shock—Etoposide—lung cancer	0.00216	0.00239	CcSEcCtD
Gonadorelin—Diarrhoea—Vinorelbine—lung cancer	0.00216	0.00238	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Irinotecan—lung cancer	0.00213	0.00235	CcSEcCtD
Gonadorelin—Anaphylactic shock—Paclitaxel—lung cancer	0.00212	0.00234	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Methotrexate—lung cancer	0.00212	0.00234	CcSEcCtD
Gonadorelin—Shock—Paclitaxel—lung cancer	0.00209	0.0023	CcSEcCtD
Gonadorelin—Nervous system disorder—Paclitaxel—lung cancer	0.00208	0.0023	CcSEcCtD
Gonadorelin—Breast disorder—Doxorubicin—lung cancer	0.00206	0.00228	CcSEcCtD
Gonadorelin—Abdominal pain—Irinotecan—lung cancer	0.00205	0.00227	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Cisplatin—lung cancer	0.00204	0.00225	CcSEcCtD
Gonadorelin—Pain—Cisplatin—lung cancer	0.00202	0.00223	CcSEcCtD
Gonadorelin—Vomiting—Vinorelbine—lung cancer	0.002	0.00221	CcSEcCtD
Gonadorelin—Headache—Vinorelbine—lung cancer	0.00197	0.00218	CcSEcCtD
Gonadorelin—Hypersensitivity—Irinotecan—lung cancer	0.00192	0.00212	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—ANXA1—lung cancer	0.00191	0.0201	CbGpPWpGaD
Gonadorelin—Nausea—Vinorelbine—lung cancer	0.00187	0.00207	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Etoposide—lung cancer	0.00187	0.00206	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GIPR—lung cancer	0.00187	0.0197	CbGpPWpGaD
Gonadorelin—Asthenia—Irinotecan—lung cancer	0.00187	0.00206	CcSEcCtD
Gonadorelin—Fatigue—Etoposide—lung cancer	0.00186	0.00206	CcSEcCtD
Gonadorelin—Constipation—Etoposide—lung cancer	0.00185	0.00204	CcSEcCtD
Gonadorelin—Pain—Etoposide—lung cancer	0.00185	0.00204	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Doxorubicin—lung cancer	0.00183	0.00202	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00183	0.00202	CcSEcCtD
Gonadorelin—Fatigue—Paclitaxel—lung cancer	0.00183	0.00202	CcSEcCtD
Gonadorelin—Asthenia—Gemcitabine—lung cancer	0.00182	0.00201	CcSEcCtD
Gonadorelin—Pain—Paclitaxel—lung cancer	0.00181	0.002	CcSEcCtD
Gonadorelin—Constipation—Paclitaxel—lung cancer	0.00181	0.002	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—APP—lung cancer	0.00181	0.0191	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Docetaxel—lung cancer	0.0018	0.00199	CcSEcCtD
Gonadorelin—Pruritus—Gemcitabine—lung cancer	0.00179	0.00198	CcSEcCtD
Gonadorelin—Diarrhoea—Irinotecan—lung cancer	0.00178	0.00196	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Etoposide—lung cancer	0.00177	0.00195	CcSEcCtD
Gonadorelin—Shock—Docetaxel—lung cancer	0.00177	0.00195	CcSEcCtD
Gonadorelin—Nervous system disorder—Docetaxel—lung cancer	0.00176	0.00195	CcSEcCtD
Gonadorelin—Hypersensitivity—Cisplatin—lung cancer	0.00174	0.00192	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Paclitaxel—lung cancer	0.00173	0.00192	CcSEcCtD
Gonadorelin—Diarrhoea—Gemcitabine—lung cancer	0.00173	0.00191	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.00172	0.0181	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.00172	0.0181	CbGpPWpGaD
Gonadorelin—Abdominal pain—Etoposide—lung cancer	0.00171	0.00189	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—lung cancer	0.00171	0.018	CbGpPWpGaD
Gonadorelin—Asthenia—Cisplatin—lung cancer	0.00169	0.00187	CcSEcCtD
Gonadorelin—Abdominal pain—Paclitaxel—lung cancer	0.00168	0.00185	CcSEcCtD
Gonadorelin—Angiopathy—Methotrexate—lung cancer	0.00165	0.00183	CcSEcCtD
Gonadorelin—Vomiting—Irinotecan—lung cancer	0.00165	0.00183	CcSEcCtD
Gonadorelin—Immune system disorder—Methotrexate—lung cancer	0.00165	0.00182	CcSEcCtD
Gonadorelin—Headache—Irinotecan—lung cancer	0.00163	0.0018	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—APP—lung cancer	0.00162	0.0171	CbGpPWpGaD
Gonadorelin—Diarrhoea—Cisplatin—lung cancer	0.00161	0.00178	CcSEcCtD
Gonadorelin—Vomiting—Gemcitabine—lung cancer	0.00161	0.00178	CcSEcCtD
Gonadorelin—Hypersensitivity—Etoposide—lung cancer	0.00159	0.00176	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GRM8—lung cancer	0.00159	0.0168	CbGpPWpGaD
Gonadorelin—Erythema—Methotrexate—lung cancer	0.00159	0.00175	CcSEcCtD
Gonadorelin—Headache—Gemcitabine—lung cancer	0.00159	0.00175	CcSEcCtD
Gonadorelin—Hypersensitivity—Paclitaxel—lung cancer	0.00156	0.00173	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Docetaxel—lung cancer	0.00155	0.00171	CcSEcCtD
Gonadorelin—Asthenia—Etoposide—lung cancer	0.00155	0.00171	CcSEcCtD
Gonadorelin—Fatigue—Docetaxel—lung cancer	0.00155	0.00171	CcSEcCtD
Gonadorelin—Nausea—Irinotecan—lung cancer	0.00154	0.00171	CcSEcCtD
Gonadorelin—Constipation—Docetaxel—lung cancer	0.00154	0.0017	CcSEcCtD
Gonadorelin—Pain—Docetaxel—lung cancer	0.00154	0.0017	CcSEcCtD
Gonadorelin—Pruritus—Etoposide—lung cancer	0.00153	0.00169	CcSEcCtD
Gonadorelin—Asthenia—Paclitaxel—lung cancer	0.00152	0.00168	CcSEcCtD
Gonadorelin—Nausea—Gemcitabine—lung cancer	0.0015	0.00166	CcSEcCtD
Gonadorelin—Vomiting—Cisplatin—lung cancer	0.0015	0.00166	CcSEcCtD
Gonadorelin—Pruritus—Paclitaxel—lung cancer	0.0015	0.00166	CcSEcCtD
Gonadorelin—Diarrhoea—Etoposide—lung cancer	0.00148	0.00163	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Docetaxel—lung cancer	0.00147	0.00162	CcSEcCtD
Gonadorelin—Diarrhoea—Paclitaxel—lung cancer	0.00145	0.0016	CcSEcCtD
Gonadorelin—Angiopathy—Doxorubicin—lung cancer	0.00143	0.00158	CcSEcCtD
Gonadorelin—Immune system disorder—Doxorubicin—lung cancer	0.00143	0.00158	CcSEcCtD
Gonadorelin—Abdominal pain—Docetaxel—lung cancer	0.00142	0.00157	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—AVP—lung cancer	0.00141	0.0148	CbGpPWpGaD
Gonadorelin—Nausea—Cisplatin—lung cancer	0.0014	0.00155	CcSEcCtD
Gonadorelin—Vomiting—Etoposide—lung cancer	0.00137	0.00152	CcSEcCtD
Gonadorelin—Erythema—Doxorubicin—lung cancer	0.00137	0.00152	CcSEcCtD
Gonadorelin—Headache—Etoposide—lung cancer	0.00135	0.0015	CcSEcCtD
Gonadorelin—Flatulence—Doxorubicin—lung cancer	0.00135	0.0015	CcSEcCtD
Gonadorelin—Vomiting—Paclitaxel—lung cancer	0.00135	0.00149	CcSEcCtD
Gonadorelin—Headache—Paclitaxel—lung cancer	0.00133	0.00147	CcSEcCtD
Gonadorelin—Hypersensitivity—Docetaxel—lung cancer	0.00132	0.00146	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GRP—lung cancer	0.00131	0.0138	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—OXTR—lung cancer	0.00131	0.0138	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Methotrexate—lung cancer	0.0013	0.00143	CcSEcCtD
Gonadorelin—Asthenia—Docetaxel—lung cancer	0.00129	0.00142	CcSEcCtD
Gonadorelin—Nausea—Etoposide—lung cancer	0.00128	0.00142	CcSEcCtD
Gonadorelin—Pruritus—Docetaxel—lung cancer	0.00127	0.0014	CcSEcCtD
Gonadorelin—Nervous system disorder—Methotrexate—lung cancer	0.00127	0.0014	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.00126	0.0133	CbGpPWpGaD
Gonadorelin—Nausea—Paclitaxel—lung cancer	0.00126	0.00139	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—lung cancer	0.00126	0.0133	CbGpPWpGaD
Gonadorelin—Diarrhoea—Docetaxel—lung cancer	0.00123	0.00136	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—GNG11—lung cancer	0.00122	0.0129	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.0012	0.0126	CbGpPWpGaD
Gonadorelin—Vomiting—Docetaxel—lung cancer	0.00114	0.00126	CcSEcCtD
Gonadorelin—Headache—Docetaxel—lung cancer	0.00113	0.00124	CcSEcCtD
Gonadorelin—Anaphylactic shock—Doxorubicin—lung cancer	0.00112	0.00124	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Methotrexate—lung cancer	0.00112	0.00124	CcSEcCtD
Gonadorelin—Fatigue—Methotrexate—lung cancer	0.00112	0.00123	CcSEcCtD
Gonadorelin—Pain—Methotrexate—lung cancer	0.00111	0.00122	CcSEcCtD
Gonadorelin—Shock—Doxorubicin—lung cancer	0.0011	0.00122	CcSEcCtD
Gonadorelin—Nervous system disorder—Doxorubicin—lung cancer	0.0011	0.00121	CcSEcCtD
Gonadorelin—Nausea—Docetaxel—lung cancer	0.00107	0.00118	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Methotrexate—lung cancer	0.00106	0.00117	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GIPR—lung cancer	0.00105	0.0111	CbGpPWpGaD
Gonadorelin—Abdominal pain—Methotrexate—lung cancer	0.00102	0.00113	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—PTHLH—lung cancer	0.00102	0.0108	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000968	0.00107	CcSEcCtD
Gonadorelin—Fatigue—Doxorubicin—lung cancer	0.000967	0.00107	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ANXA1—lung cancer	0.000962	0.0101	CbGpPWpGaD
Gonadorelin—Constipation—Doxorubicin—lung cancer	0.000959	0.00106	CcSEcCtD
Gonadorelin—Pain—Doxorubicin—lung cancer	0.000959	0.00106	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GIPR—lung cancer	0.000958	0.0101	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Methotrexate—lung cancer	0.000954	0.00105	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000931	0.00983	CbGpPWpGaD
Gonadorelin—Asthenia—Methotrexate—lung cancer	0.000929	0.00103	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Doxorubicin—lung cancer	0.000917	0.00101	CcSEcCtD
Gonadorelin—Pruritus—Methotrexate—lung cancer	0.000916	0.00101	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—APP—lung cancer	0.000912	0.00962	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GRM8—lung cancer	0.000897	0.00947	CbGpPWpGaD
Gonadorelin—Abdominal pain—Doxorubicin—lung cancer	0.000887	0.000979	CcSEcCtD
Gonadorelin—Diarrhoea—Methotrexate—lung cancer	0.000886	0.000979	CcSEcCtD
Gonadorelin—Hypersensitivity—Doxorubicin—lung cancer	0.000826	0.000913	CcSEcCtD
Gonadorelin—Vomiting—Methotrexate—lung cancer	0.000823	0.00091	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000815	0.0086	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GRM8—lung cancer	0.000814	0.0086	CbGpPWpGaD
Gonadorelin—Headache—Methotrexate—lung cancer	0.000811	0.000896	CcSEcCtD
Gonadorelin—Asthenia—Doxorubicin—lung cancer	0.000805	0.000889	CcSEcCtD
Gonadorelin—Pruritus—Doxorubicin—lung cancer	0.000793	0.000876	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.000777	0.0082	CbGpPWpGaD
Gonadorelin—Nausea—Methotrexate—lung cancer	0.000769	0.00085	CcSEcCtD
Gonadorelin—Diarrhoea—Doxorubicin—lung cancer	0.000767	0.000848	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—AXL—lung cancer	0.000747	0.00788	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—OXTR—lung cancer	0.000739	0.0078	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GRP—lung cancer	0.000739	0.0078	CbGpPWpGaD
Gonadorelin—Vomiting—Doxorubicin—lung cancer	0.000713	0.000788	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—AVP—lung cancer	0.000709	0.00748	CbGpPWpGaD
Gonadorelin—Headache—Doxorubicin—lung cancer	0.000703	0.000776	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—GNG11—lung cancer	0.000691	0.0073	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000689	0.00727	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—OXTR—lung cancer	0.000671	0.00708	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GRP—lung cancer	0.000671	0.00708	CbGpPWpGaD
Gonadorelin—Nausea—Doxorubicin—lung cancer	0.000666	0.000736	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—GNG11—lung cancer	0.000628	0.00663	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ADCY1—lung cancer	0.000622	0.00656	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000619	0.00653	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—COL4A2—lung cancer	0.000581	0.00613	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PTHLH—lung cancer	0.000578	0.0061	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GIPR—lung cancer	0.000566	0.00597	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADCY1—lung cancer	0.000565	0.00596	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PPP2R1B—lung cancer	0.00055	0.00581	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ANXA1—lung cancer	0.000543	0.00574	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SDC4—lung cancer	0.000528	0.00558	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PTHLH—lung cancer	0.000525	0.00554	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	0.000518	0.00547	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—DUSP3—lung cancer	0.000518	0.00546	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—APP—lung cancer	0.000515	0.00544	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RHEB—lung cancer	0.000508	0.00536	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	0.000497	0.00524	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ANXA1—lung cancer	0.000493	0.00521	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GRM8—lung cancer	0.000481	0.00508	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000479	0.00505	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	0.000472	0.00499	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—POMC—lung cancer	0.000471	0.00497	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—APP—lung cancer	0.000468	0.00494	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SKI—lung cancer	0.000466	0.00492	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—PIK3CA—lung cancer	0.000458	0.00484	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	0.000446	0.00471	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	0.00041	0.00433	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PXN—lung cancer	0.000405	0.00427	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AVP—lung cancer	0.000401	0.00423	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GRP—lung cancer	0.000396	0.00418	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKR1C1—lung cancer	0.000396	0.00418	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—OXTR—lung cancer	0.000396	0.00418	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	0.000379	0.004	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GNG11—lung cancer	0.000371	0.00391	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL8—lung cancer	0.000364	0.00385	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AVP—lung cancer	0.000364	0.00384	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	0.000363	0.00383	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFC—lung cancer	0.000353	0.00373	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADCY1—lung cancer	0.000334	0.00352	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PPP2R1B—lung cancer	0.000325	0.00343	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SMARCA4—lung cancer	0.000325	0.00343	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HSPB1—lung cancer	0.000314	0.00331	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTHLH—lung cancer	0.00031	0.00327	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ANXA1—lung cancer	0.000292	0.00308	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FLT1—lung cancer	0.000282	0.00298	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CG—lung cancer	0.00028	0.00295	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH3—lung cancer	0.000276	0.00292	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APP—lung cancer	0.000276	0.00292	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF9—lung cancer	0.000274	0.00289	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—POMC—lung cancer	0.000266	0.00281	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JUNB—lung cancer	0.000262	0.00276	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CG—lung cancer	0.000254	0.00268	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CD—lung cancer	0.000246	0.0026	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—POMC—lung cancer	0.000242	0.00255	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STK11—lung cancer	0.000238	0.00251	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6R—lung cancer	0.000236	0.00249	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FOXO3—lung cancer	0.000229	0.00242	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MAP2K1—lung cancer	0.000225	0.00237	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CD—lung cancer	0.000223	0.00236	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AVP—lung cancer	0.000215	0.00227	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CB—lung cancer	0.000214	0.00226	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1R—lung cancer	0.000207	0.00218	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL8—lung cancer	0.000206	0.00217	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HES1—lung cancer	0.000203	0.00214	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—RAF1—lung cancer	0.000199	0.0021	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—IL2—lung cancer	0.000197	0.00208	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CB—lung cancer	0.000195	0.00205	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL8—lung cancer	0.000187	0.00197	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB3—lung cancer	0.000186	0.00196	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL2—lung cancer	0.000179	0.00189	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TERT—lung cancer	0.000178	0.00188	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGFR1—lung cancer	0.000173	0.00183	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIF1A—lung cancer	0.00017	0.0018	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APOA1—lung cancer	0.000164	0.00173	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KDR—lung cancer	0.000163	0.00172	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APC—lung cancer	0.00015	0.00158	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CG—lung cancer	0.00015	0.00158	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KIT—lung cancer	0.00015	0.00158	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—NRAS—lung cancer	0.00015	0.00158	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGF—lung cancer	0.000148	0.00157	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MAPK3—lung cancer	0.000144	0.00152	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—POMC—lung cancer	0.000143	0.00151	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—BRAF—lung cancer	0.000141	0.00149	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6R—lung cancer	0.000139	0.00147	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CREBBP—lung cancer	0.000139	0.00147	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EGFR—lung cancer	0.000137	0.00144	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAP2K1—lung cancer	0.000133	0.0014	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CD—lung cancer	0.000132	0.00139	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CA—lung cancer	0.000131	0.00138	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—KRAS—lung cancer	0.000129	0.00136	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CA—lung cancer	0.000119	0.00125	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MDM2—lung cancer	0.000118	0.00125	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RAF1—lung cancer	0.000118	0.00124	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB2—lung cancer	0.000116	0.00123	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CB—lung cancer	0.000115	0.00121	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MTOR—lung cancer	0.000115	0.00121	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL8—lung cancer	0.00011	0.00117	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—HRAS—lung cancer	0.00011	0.00116	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT1—lung cancer	0.000107	0.00113	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CASP3—lung cancer	0.000106	0.00112	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL2—lung cancer	0.000106	0.00111	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6—lung cancer	0.000105	0.00111	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCND1—lung cancer	0.000103	0.00109	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JUN—lung cancer	0.000103	0.00108	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP9—lung cancer	9.99e-05	0.00105	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1A—lung cancer	9.96e-05	0.00105	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTEN—lung cancer	9.93e-05	0.00105	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT1—lung cancer	9.69e-05	0.00102	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EP300—lung cancer	9.47e-05	0.001	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SRC—lung cancer	9.21e-05	0.000972	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFA—lung cancer	8.97e-05	0.000947	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STAT3—lung cancer	8.88e-05	0.000938	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NRAS—lung cancer	8.86e-05	0.000935	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAPK3—lung cancer	8.49e-05	0.000896	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MYC—lung cancer	8.26e-05	0.000871	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGFR—lung cancer	8.07e-05	0.000852	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KRAS—lung cancer	7.63e-05	0.000805	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CA—lung cancer	7.01e-05	0.00074	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TP53—lung cancer	6.78e-05	0.000716	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HRAS—lung cancer	6.48e-05	0.000684	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6—lung cancer	6.21e-05	0.000655	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT1—lung cancer	5.73e-05	0.000604	CbGpPWpGaD
